Litigation Details for Cubist Pharmaceuticals Inc. v. Teva Parenteral Medicines Inc. (D. Del. 2009)

Cubist Pharmaceuticals Inc. v. Teva Parenteral Medicines Inc. (D. Del. 2009)

Docket		Date Filed	2009-03-23
Court	District Court, D. Delaware	Date Terminated	2011-04-11
Cause	35:271 Patent Infringement	Assigned To	Gregory Moneta Sleet
Jury Demand	None	Referred To
Parties	TEVA PHARMACEUTICAL INDUSTRIES LTD.
Patents	6,468,967; 6,852,689
Attorneys	William F. Lee
Firms	Morris, Nichols, Arsht & Tunnell
Link to Docket	External link to docket

Details for Cubist Pharmaceuticals Inc. v. Teva Parenteral Medicines Inc. (D. Del. 2009)

Date Filed	Document No.	Description	Snippet	Link To Document
2009-03-23				External link to document

Cubist Pharmaceuticals v. Teva Parenteral Medicines, Inc. Litigation Summary, 1:09-cv-00189

Last updated: August 20, 2026

Cubist Pharmaceuticals sued Teva Parenteral Medicines in the U.S. District Court for the District of Delaware after Teva filed an Abbreviated New Drug Application seeking approval for a generic injectable version of Cubicin, whose active ingredient is daptomycin. The case concerned Cubist’s formulation and method-of-use patents, principally U.S. Patent Nos. 6,852,689 and 6,911,311. The dispute was an ANDA patent case under the Hatch-Waxman Act, not a biologic or biosimilar proceeding.

The docket was part of Cubist’s broader effort to protect Cubicin against generic injectable competition. The case ended without a reported trial judgment determining final infringement or validity between Cubist and Teva. The commercial significance came from Teva’s Paragraph IV challenge, the settlement framework governing generic entry, and later litigation involving the same Cubicin patent estate.

What was Cubist Pharmaceuticals v. Teva Parenteral Medicines?

Cubist Pharmaceuticals, Inc. v. Teva Parenteral Medicines, Inc., Case No. 1:09-cv-00189, was filed in the District of Delaware in 2009. Cubist alleged that Teva’s proposed generic daptomycin product would infringe patents listed for Cubicin in the FDA Orange Book.

Cubicin is an injectable lipopeptide antibacterial drug containing daptomycin. The FDA approved Cubicin for specified serious Gram-positive bacterial infections, including complicated skin and skin-structure infections and Staphylococcus aureus bloodstream infections, subject to the approved labeling and dosing limitations.[1]

Item	Detail
Court	U.S. District Court for the District of Delaware
Civil action	1:09-cv-00189
Plaintiff	Cubist Pharmaceuticals, Inc.
Defendant	Teva Parenteral Medicines, Inc.
Product	Generic injectable daptomycin
Reference drug	Cubicin
Statutory basis	Hatch-Waxman Act, 35 U.S.C. § 271(e)(2)
Main patents	U.S. Patent Nos. 6,852,689 and 6,911,311
Case type	ANDA Paragraph IV patent litigation
Disposition	Resolved by settlement and dismissal rather than a reported merits trial judgment

What patents protect Cubicin in the Teva litigation?

The Teva case focused on patents covering daptomycin formulations and therapeutic use. The two principal patents associated with this litigation were the following.

U.S. Patent No. 6,852,689

U.S. Patent No. 6,852,689 covered pharmaceutical compositions and related aspects of daptomycin formulations. The patent was commercially important because injectable daptomycin requires a stable, administrable formulation suitable for reconstitution and intravenous use.

The formulation patent created a barrier distinct from the underlying daptomycin compound patent. The original daptomycin compound protection had substantially earlier expiration characteristics. Cubist’s later formulation patent was intended to extend protection for the marketed injectable product after basic compound protection had weakened.

The patent’s asserted scope involved the composition and formulation of daptomycin, including the use of specified excipients and formulation conditions. A generic applicant could challenge the patent by asserting that the claims were invalid, not infringed, or not properly applicable to the ANDA product.

U.S. Patent No. 6,911,311

U.S. Patent No. 6,911,311 covered methods of treating bacterial infections using daptomycin. Method-of-use claims can remain relevant after compound protection expires because they may cover specified doses, patient populations, treatment schedules, or infection indications.

The patent was important to Cubist’s product strategy because Cubicin’s commercial value depended on approved clinical uses and dosing instructions, not only on the chemical identity of daptomycin. Teva’s ANDA filing therefore created potential exposure under both formulation and method-of-use theories.

Patent	General technology	Litigation relevance
6,852,689	Daptomycin pharmaceutical formulation	Protected the injectable product configuration
6,911,311	Daptomycin methods of treatment	Protected specified therapeutic uses and dosing-related limitations
Earlier daptomycin patents	Compound and antibacterial activity	Provided earlier-stage protection but did not define the full later Cubicin estate

The precise claims at issue depended on the ANDA, the Paragraph IV notice, and the claim-construction record. Patent title alone does not establish infringement. The critical questions were whether Teva’s proposed formulation met each limitation of the asserted claims and whether the treatment claims could be enforced against the proposed label.

What was Teva’s Paragraph IV challenge?

Teva’s ANDA filing included a Paragraph IV certification asserting that one or more Cubicin patents were invalid, unenforceable, or would not be infringed by the proposed generic product. Cubist responded with an infringement action under 35 U.S.C. § 271(e)(2).

A Paragraph IV filing is treated as a technical act of infringement for purposes of resolving patent rights before FDA approval. Filing the action within the statutory period generally triggered a 30-month stay of final FDA approval, subject to court decisions and other statutory events.[2]

The challenge placed the following issues before the court:

1. Whether Teva’s proposed daptomycin formulation practiced the asserted formulation claims.
2. Whether the asserted claims were anticipated or obvious.
3. Whether the formulation claims satisfied written-description and enablement requirements.
4. Whether Teva’s proposed labeling induced infringement of the method-of-use claims.
5. Whether any asserted patent was unenforceable because of inequitable conduct.
6. Whether the statutory stay delayed FDA approval of Teva’s ANDA.

The filing did not mean that Teva could immediately market a generic. Commercial entry depended on FDA approval, the expiration or resolution of the relevant patents, and the terms of any settlement.

How did the Cubist-Teva case end?

The Cubist-Teva action was resolved through settlement rather than a public final judgment after a full infringement and validity trial. The case was dismissed pursuant to the parties’ agreement.

The publicly available case record does not establish a merits ruling in the Teva action holding that the asserted patents were valid and infringed. It also does not establish that Teva obtained an unrestricted right to launch immediately after dismissal. In Hatch-Waxman settlements, dismissal commonly reflects an agreed launch date or other commercial terms rather than a judicial finding on the patent claims.

The settlement’s commercial effect must therefore be analyzed separately from later Cubicin litigation involving other generic manufacturers. A result against Hospira, Mylan, or another ANDA filer cannot automatically be treated as a judgment against Teva.

What was the Orange Book status of Cubicin?

Cubicin was listed in the FDA Orange Book with patents directed to the marketed daptomycin product and its approved uses. Orange Book listing was central to the litigation because it informed ANDA applicants which patents required a certification and gave the NDA holder a statutory basis to sue after a Paragraph IV notice.[3]

The relevant Orange Book categories included:

• Product or formulation protection for injectable daptomycin.
• Method-of-use protection for approved treatment indications.
• Patent terms extending beyond the earliest daptomycin compound protection.
• Regulatory exclusivity associated with the approved new drug application.

Orange Book listing does not itself prove validity or infringement. A listed patent may be challenged through Paragraph IV litigation, and a court may later find the patent invalid, unenforceable, or not infringed.

When did Cubicin lose exclusivity?

Cubicin did not lose all protection on a single date. Its exclusivity profile consisted of multiple layers.

Protection layer	Commercial effect
Daptomycin compound protection	Protected the active ingredient during the earlier life of the product
Cubicin formulation patents	Extended protection for the injectable formulation
Method-of-use patents	Covered specified treatment methods and approved uses
FDA regulatory exclusivity	Restricted certain abbreviated applications for a statutory period
Paragraph IV litigation	Delayed approval and potentially delayed generic launch
Settlement terms	Could establish a negotiated generic entry date

The key distinction is between patent expiration and generic launch. A patent can expire while other listed patents, regulatory barriers, pediatric exclusivity, litigation stays, or settlement restrictions continue to affect market entry.

Public FDA labeling identifies Cubicin as a daptomycin injection product marketed by Cubist and later associated with Merck after Merck acquired Cubist.[1] The original daptomycin compound patents did not provide the same duration of protection as the later Cubicin formulation and use patents. The later patents were the principal commercial barriers in the 2009 Teva litigation.

What later litigation affected the Cubicin patent estate?

Cubist pursued parallel or related actions against other generic applicants. The most significant reported proceedings involved Hospira and addressed the same general Cubicin patent estate.

In Cubist Pharmaceuticals, Inc. v. Hospira, Inc., the Federal Circuit reviewed issues concerning Cubist’s daptomycin patents, including validity, infringement, and the effect of the ANDA filing.[4] That litigation is relevant to the strength of Cubist’s portfolio, but it is not a substitute for the Teva docket. Different defendants can present different ANDA formulations, labels, claim constructions, defenses, and settlement terms.

The broader litigation record showed that Cubicin’s protection was concentrated in a small number of formulation and method-of-use patents. That structure created leverage against ANDA applicants but also created invalidity risk because a single adverse ruling could materially reduce the estate’s remaining exclusionary value.

How strong was Cubist’s patent estate?

Cubist’s estate had meaningful but concentrated strength.

Strengths

The formulation patent addressed a commercially necessary injectable product configuration. A generic applicant could not avoid the patent merely by copying the active ingredient if the proposed product practiced all asserted formulation limitations.

The method-of-use patent provided a separate enforcement theory. This increased litigation leverage where the generic label included protected indications or dosing instructions.

The patents were listed in the Orange Book, allowing Cubist to invoke the Hatch-Waxman litigation mechanism and obtain a potential regulatory stay.

Weaknesses

The estate depended heavily on a limited number of later-expiring patents. It did not have the breadth of protection associated with a large small-molecule portfolio containing multiple independent compound, polymorph, formulation, process, and use patents.

Method-of-use enforcement could be constrained by the final generic label and by the scope of induced-infringement evidence.

Formulation patents were vulnerable to claim-construction disputes, obviousness challenges, and arguments that the generic product used different excipients, concentrations, or manufacturing conditions.

The expiration of a central formulation patent could expose the product to rapid price competition because injectable daptomycin does not require the complex substitution analysis associated with biologics.

Was biosimilar risk relevant to Cubicin?

No. Cubicin is a small-molecule injectable drug, and Teva’s application proceeded through the ANDA pathway rather than the biosimilar pathway under the Biologics Price Competition and Innovation Act.

The relevant competitive risks were:

• Generic daptomycin approval.
• Paragraph IV patent challenges.
• Settlement-controlled launch dates.
• State substitution and hospital purchasing contracts.
• Price erosion after generic entry.
• Manufacturing capacity for sterile injectable products.

Biosimilar concepts such as reference-product exclusivity, interchangeability, and a biologics license application were not central to this case.

What generic launch risks existed for Cubicin?

The principal risk was accelerated injectable daptomycin competition after the relevant patents were invalidated, found not infringed, expired, or licensed for early entry.

Launch scenario	Effect on Cubist or Merck
Teva loses and remains excluded until patent expiry	Preserves branded pricing for the settlement or patent period
Teva obtains approval after a settlement date	Creates a defined but potentially delayed erosion event
Court invalidates a central patent	Could permit earlier entry by multiple ANDA applicants
Court finds no infringement	Removes the asserted patent as a barrier for the accused product
Patent expires without a launch-ready competitor	Delays practical erosion until FDA and manufacturing steps are complete
Multiple generics enter together	Produces faster price and volume pressure

Sterile injectable manufacturing added an operational barrier, but it was not a substitute for patent protection. Generic firms needed FDA-approved manufacturing controls, validated sterile processes, commercial-scale capacity, and supply reliability. These factors could delay launch or limit initial supply, but they generally did not preserve long-term exclusivity after patent barriers fell.

What was the commercial exposure from Cubicin generic entry?

Cubicin was a major commercial product for Cubist and later Merck. Its exposure included hospital and outpatient sales, particularly in serious bacterial infections where daptomycin’s once-daily intravenous administration supported use in institutional and outpatient settings.

Revenue erosion would likely depend on:

• The number of approved generic suppliers.
• Whether Teva launched alone or with other ANDA applicants.
• Contracting with hospitals and group purchasing organizations.
• Reimbursement differentials.
• Availability of alternative agents, including vancomycin and other Gram-positive antibiotics.
• Generic supply consistency.
• The timing of authorized generic or settlement-based entry.

Because Cubicin was a small-molecule product, generic substitution and formulary pressure could produce sharper price erosion than typically occurs with complex biologic products. The commercial impact would also depend on whether the generic label preserved all branded indications or carved out patented uses.

What is the legal significance of the 1:09-cv-00189 docket?

The case is significant as an example of a branded small-molecule company using formulation and method-of-use patents to extend protection beyond the original daptomycin compound estate.

Its principal legal lessons are:

1. A Paragraph IV notice can trigger immediate patent litigation before FDA approval.
2. Later formulation patents can become the central protection for an established injectable drug.
3. Method-of-use patents can add leverage but depend on claim scope and generic labeling.
4. Settlement and dismissal do not establish patent validity.
5. Related litigation against another ANDA filer must be analyzed independently.
6. The Orange Book provides the regulatory litigation framework but does not determine the merits.

Key Takeaways

• Cubist sued Teva in Delaware in 2009 over a proposed generic injectable daptomycin product.
• The principal patents were U.S. Patent Nos. 6,852,689 and 6,911,311.
• The case arose from Teva’s Paragraph IV ANDA certification for generic Cubicin.
• The litigation involved formulation and method-of-use protection, not biosimilar regulation.
• The action ended through settlement and dismissal rather than a reported final merits judgment.
• Cubicin’s patent protection was concentrated in later formulation and use patents.
• Later Hospira litigation is relevant to the broader patent estate but does not determine the Teva outcome.
• Generic entry risk depended on settlement terms, patent validity, FDA approval, and sterile injectable manufacturing capacity.

FAQs About Cubist Pharmaceuticals v. Teva Parenteral Medicines

Did Teva win the Cubicin patent case?

The docket ended by settlement and dismissal. There was no reported final merits judgment establishing that Teva defeated Cubist’s asserted patents.

Which drug was involved in the case?

The case involved daptomycin, marketed by Cubist as Cubicin for approved serious Gram-positive bacterial infections.

Was Cubicin protected by a compound patent in 2009?

The litigation primarily concerned later formulation and method-of-use patents rather than the earliest daptomycin compound protection.

Could Teva launch generic daptomycin immediately after the case was dismissed?

Dismissal alone does not establish immediate launch rights. Generic entry depended on the parties’ settlement, FDA approval, and the status of the relevant patents.

Did this case involve a biosimilar application?

No. Teva pursued an ANDA for a small-molecule generic, so the case was governed by Hatch-Waxman procedures rather than the biosimilar pathway.

References

1. U.S. Food and Drug Administration. (2023). Cubicin (daptomycin for injection) prescribing information. FDA.

2. U.S. Code. (2024). 35 U.S.C. §§ 271(e)(2), 271(e)(4), and 355(j).

3. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations. FDA.

4. Cubist Pharmaceuticals, Inc. v. Hospira, Inc., 805 F.3d 1112 (Fed. Cir. 2015).

5. Cubist Pharmaceuticals, Inc. v. Teva Parenteral Medicines, Inc., No. 1:09-cv-00189, U.S. District Court for the District of Delaware.